Download the instructions for Riflimab: Detailed explanation of indications, usage and dosage

Retifanlimab - Zynyz is a humanized IgG4 monoclonal antibody with the trade name Zynyz. It is a programmed death receptor-1 (PD-1) inhibitor developed and commercialized by Incyte. As a new member of the immune checkpoint inhibitor family, Zynyz relieves the immunosuppressive effect of T cells in the tumor microenvironment by blocking the binding of PD-1 and its ligands PD-L1/PD-L2, thereby restoring the body's anti-tumor immune function. This mechanism has been proven in a variety of malignant tumors to significantly extend the progression-free survival and overall survival of patients. It is one of the important breakthroughs in the field of immuno-oncology treatment in recent years.

Currently, the U.S.FDA has approved Zynyz for the treatment of two major types of solid tumors, includingMerkel cell carcinoma (MCC) and squamous cell carcinoma of the anal canal (SCAC), both targeting adults with advanced or metastatic disease. First, for MCC, Zynyz is indicated for advanced or recurrent cases that are unable to undergo local surgical resection or radiotherapy. Since Merkel cell carcinoma is an extremely rare but rapidly progressing cutaneous neuroendocrine malignant tumor, traditional treatments are limited, and immune checkpoint inhibitors provide a practical and effective treatment path for this disease. Zynyz improves the elimination ability of MCC cells by activating antigen-specific T cells, and has demonstrated good response rates and duration in clinical studies.

Secondly, in terms of anal canal squamous cell carcinoma,Zynyz is suitable for two scenarios: first, as a first-line treatment, used in combination with carboplatin and paclitaxel (Paclitaxel) to treat adult patients with inoperable locally recurrent or metastatic SCAC; second, when patients progress or are intolerant during standard platinum-based chemotherapy, Zynyz can be used as a single-agent treatment. This multi-level indication setting reflects the breadth of application of its immune mechanism in tumor management at different stages, and also shows its strategic position in immunotherapy combination programs.

In terms of usage and dosage,The recommended dose of Zynyz is 500mg, which should be infused intravenously for 30 minutes each time and administered once every 4 weeks. This relatively simple medication regimen makes it more convenient and compliance-friendly in actual clinical operations. It is worth emphasizing that the drug does not require fixed dosing based on weight conversion, simplifying the individual dose adjustment process. The immunotherapy cycle of Zynyz depends on the patient's disease response. Doctors will determine the timing of continuation or termination of the treatment based on imaging evaluation and immune-related toxicity.

In addition, it should be noted that as an immunosuppressant,Zynyz may cause immune-related side effects, such as rash, enteritis, hepatitis, endocrine disorders, etc. Therefore, patients' liver and kidney function, thyroid function and other related inflammatory indicators need to be closely monitored during use. For patients who experience immune-mediated side effects, a short-term interruption of treatment may be required, and management may be supplemented by glucocorticoids or other immunosuppressive agents if necessary.

CurrentlyZynyz has not been approved for marketing in mainland China, nor has it been included in the national medical insurance drug list. If domestic patients want to use the drug, they can generally obtain the original version through overseas drug purchasing services or international hospital channels.

Reference materials:https://www.drugs.com/mtm/retifanlimab.html